The global incidence of melanoma is increasing, and the prognosis for patients remains poor. High-dose interferon-alpha (HD-IFN-a) and pegylated IFN are the only US Food and Drug Administration (FDA)-approved agents for adjuvant therapy for high-risk melanoma, and an improvement in relapse-free survival (RFS) has been observed consistently across nearly all published studies and meta-analyses. Some studies and meta-analyses have also supported an overall survival (OS) benefit. However, despite a number of adjuvant studies, controversy remains regarding the role of this treatment. As the benefits in OS are modest with IFN treatment, there is therefore a need for new therapeutic targets, new drugs, and optimum patient selection. Current research is investigating new adjuvant agents, either individually or in combination, which may advance the standard of care beyond HD-IFN. Additionally, identifying biomarkers of patients with greater likelihood of response may allow patient-specific therapeutic approaches. Following the recent FDA approval of ipilimumab, vemurafenib, dabrafenib, and trametenib for metastatic melanoma, ongoing adjuvant trials are now underway.
for the management of stage IV disease harboring BRAF mutations.
The current treatment for melanoma with lymph node involvement, but without distant metastasis, is surgical excision and lymph node dissection.
However, the risk for recurrence of melanoma after surgery is reported to be approximately 60 % for stage IIB patients and 75 % for stage III patients. 4 The probability of recurrence is defined as low, intermediate, or
high risk depending on the thickness of the primary tumor, the presence of ulceration or mitoses in the primary tumor, and the presence of nodal or in-transit or satellite metastases around the primary lesion. 5, 6 Adjuvant therapy is offered after surgical treatment has removed all detectable disease and is given with the intent of reducing relapse risk due to occult disease. Adjuvant therapy should be considered for patients whose risk for recurrence exceeds 30 %, i.e. patients with either stage IIB melanoma with a primary thickness greater than 4 mm or greater than 2 mm with ulceration or stage III melanoma. 4 For patients with stage I-II disease, sentinel node mapping, a procedure that identifies micro-metastatic disease in the regional lymph nodes with greater precision than an elective lymph node dissection, may be used to select patients for adjuvant therapy. This article will discuss the use of IFN-a in the adjuvant setting and will outline other evolving options including vaccines, CTLA-4 blockade, chemotherapy, and radiotherapy.
Interferon Adjuvant Therapy in Melanoma
HD interferon-alpha (HD-IFN-a) is the only FDA-approved agent for adjuvant therapy for high-risk melanoma and has shown clinical efficacy;
however, the optimal dosing and duration of treatment are still unclear.
The schedule for administration of the therapy is as follows: induction:
IFN-a: 20 MU, intravenously (IV) 5 days a week for 4 weeks; followed by maintenance: IFN-a: 10 MU, subcutaneously (SC) three times a week for 48 weeks. The FDA approved the use of adjuvant HD-IFN-a in high-risk melanoma after a pivotal phase III trial, E1684, demonstrated significant reduction of recurrence and mortality in patients with high-risk (stage IIB and IIIA/B) melanoma. 8 Treatment with HD-IFN-a prolonged the relapsefree survival (RFS) at 5 years by 40 %, and overall survival (OS) by 28 % compared with the observation group. Since the aim of the study was to administer maximally tolerated doses of IFN, toxicity was significant The duration of therapy of HD-IFN-a has been the subject of debate. In a study to determine the potential benefit of adding a short-term highdose induction phase to conventional adjuvant LD-IFN-a treatment of patients with high-risk primary melanoma, no significant differences were observed in terms of OS, or RFS when compared with a conventionally treated group of patients. 17 The Hellenic group found no differences in RFS and OS with 1 month versus 1 year of adjuvant HD-IFN-a therapy in patients with resected, high-risk (stage IIB to III) melanoma. 18 However, this trial was underpowered to achieve statistical significance. Another trial compared therapy for 1 month with therapy for 1 year for patients with intermediate-risk melanoma. The trial was stopped for futility, because the 1-month HD-IFN-a was not better than observation. It was concluded that 1 month of therapy with HD-IFN-a is insufficient to improve RFS and OS. 19 Further efforts to modify the IFN-a dose or schedule have not improved its efficacy. 20 These data suggest that the benefit of IFN-a requires more lengthy treatment than just the induction phase of the high-dose regimen. The optimal dosing and duration of treatment with IFN-a could be improved with further study, but the promise of newer agents suggests other approaches.
In a meta-analysis, no optimal IFN-a dose and/or treatment duration or a subset of patients more responsive to adjuvant therapy was identified. 21 The meta-analysis of 14 studies concluded that IFN-a treatment was These three meta-analyses and one systematic review to date have found that IFN-a treatment was associated with a statistically significant improvement RFS with a lesser impact on OS, and there is no evidence of survival gain beyond 10 years. [21] [22] [23] [24] More recently, a Cochrane review of 18
RCTs and 10,499 patients showed a RFS benefit (HR 0.83; p 0.0001) and OS benefit (HR 0.91; p=0.003). 25 In 2011, the FDA-approved pegylated IFN-a-2b (PEG-IFN-a-2b) for the adjuvant treatment of patients with high-risk melanoma, following the results of a phase III trial. 26 Long-term (7.6 years) follow-up data showed improved RFS but not OS in the treatment arm. 27 Subgroup analysis suggests that the benefit of PEG-IFN may be limited to patients with micrometastatic disease and ulcerated primaries. 27 compared with LD-IFN-a. 28 PEG-IFN-a may be considered as an alternative to HD-IFN-a for patients unwilling to undergo a high-dose regimen.
In summary, in the clinical trials of IFN-a adjuvant therapy to date, only HD-IFN-a has consistently shown an improvement of RFS in all studies and has shown an increase in OS in randomized clinical trials (RCTs).
However, it remains uncertain which patient population benefits most from adjuvant treatment. In addition, the use of IFN-a is associated with toxicity and requires a team with experience in its management. There is a need for other therapeutic regimes in adjuvant treatment of melanoma.
Current Research into Alternative Adjuvant Therapies
A number of alternative adjuvant therapies are being investigated. A summary is given in Table 2 . Unfortunately, the toxicity and complexity of the administration of this regimen is a significant barrier to making it standard practice for stage III melanoma, and make it ill-suited for a control arm in large randomized controlled trials.
Checkpoint Blockade
The use of ipilimumab as first-line treatment is well-established, 35 and clinical trials are now underway to assess its utility in the adjuvant setting.
Two clinical trials are currently ongoing for the adjuvant use of ipilimumab.
The Eastern Cooperative Oncology Group (ECOG) 1609 clinical trial is
currently underway has three treatment arms: high-dose ipilimumab, lowdose ipilimumab, and HD-IFN-a (see Figure 1) . 36 In Europe, the European Organisation for Research and Treatment of Cancer (EORTC) 18071 trial, comparing ipilimumab against placebo, has completed accrual and results are pending. 37 Given the high cost and toxicity of ipilimumab, biomarkers of response would be useful to identify relevant patient cohorts. Elevated tumor-infiltrating lymphocyte (TIL), T reg, and indoleamine 2,3-dioxygenase (IDO) levels, have been associated with improved outcomes in patients receiving ipilimumab therapy in the first-line setting. 38 
Granulocyte-macrophage Colony-stimulating Factor
Granulocyte-macrophage colony-stimulating factor (GM-CSF) may be effective as an adjuvant therapy in stage III patients. 39 A phase III trial in stage IIIB, IIIC, and IV disease, found that GM-CSF improved the RFS with minimal toxicity. 40 A single-center study has also provided evidence for the efficacy of GM-CSF in this setting. 41 There is a need for further clinical trials investigating its use and it may be that in combination with other immunotherapy we will see enhanced results.
A phase II trial found that the combination treatment regimen of GM-CSF and IL-2 in the adjuvant setting appeared to benefit high-risk melanoma patients. 42 In a new approach to adjuvant therapy, a pilot study investigated the administration of a single short course of GM-CSF and IL-2 intradermally at the primary site, prior to its excision. This very small study underscores the biological activity of GM-CSF and IL-2 when given intradermally, and suggests that although newer studies are focusing on other agents, the addition of intradermal injections of IL-2 and GM-CSF to other adjuvant treatment schemes may prove beneficial. 
Radiotherapy
Radiotherapy may be valuable in the adjuvant setting in patients with bulky disease of involvement of nodes, particularly for those with the potential for a highly symptomatic nodal relapse. 6 The use of radiotherapy as adjuvant has been investigated in a phase III trial, but although it improved regional control, it did not improve OS. 53 Further work from this group presented at this last year's ASCO confirmed the RFS advantage, but lack of OS and trend toward decreased quality of life suggest careful selection of patients where decrease in relapse outweighs the potential morbidity in terms of lymphedema risk. 
Prognostic Biomarkers and Predictive Factors for Response to Adjuvant Therapy in Melanoma
There is a need for prognostic biomarkers of IFN-a response, since identification of the ~15 % of patients who will derive benefit from IFN-a would increase the therapeutic index of this agent. Numerous candidate molecules have been studied, including methylthioadenosine phosphorylase expression, YKL-40, S100B, melanoma-inhibiting activity, and tumor-associated antigen 90 immune complex. 6 However, there is a lack of prospective data validating the use of these biomarkers.
Serum protein S100B has been demonstrated to significantly correlate with mortality risk when assessed at baseline in patients with high-risk resectable melanoma. Lower tumor stage and ulceration have been noted as predictive factors for patient response to PEG-IFN-a-2b. 27 Analysis of the results of the PEG-IFN-a trial found that ulceration of the primary tumour was not only a strong prognostic factor, but also a significant predictive factor for patient response to adjuvant IFN-a treatment. 27 There is also evidence that patients treated with IFN-a may benefit more if they have micrometastases than if they have macrometastases of the lymph nodes. 63 In addition, the appearance of autoantibodies or clinical manifestations of autoimmunity during treatment with IFN-a-2b was also associated with improvements in RFS and OS in patients with melanoma. 64 This observation was confirmed in a subsequent study 65 In the adjuvant setting it may be that given their high response rate, micrometastatic disease will be eliminated at a similarly high rate and, if so, long-term benefits would be possible without continued treatment.
Although programmed cell death 1 (PD-1) blockade appears to be an 
